Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • MapLight shares sink on mixed phase 2 schizophrenia readout

MapLight shares sink on mixed phase 2 schizophrenia readout

July 27, 2026Posted inBiotechnology

MapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.

Post navigation

Previous Post
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott
Next Post
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears

Recent Posts

  • How an industrial apparel brand stitches narrative into fabric, thread and label
  • Generative AI shows promise for renewable energy, but Africa lacks field evidence
  • Hexokinase 2 drives colorectal cancer malignancy by triggering ZNF366 protein degradation
  • New Open-Access Journal Biomedical Materials Science Launches to Link Materials Innovation with Patient Care
  • Smart Nanocarriers Promise Sustained Delivery of Biostimulants for Sustainable Crops

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top